GE HealthCare (GEHC) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] GE Healthcare Technologies Inc (GEHC) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, GE HealthCare is a large medical technology company that sells imaging systems, diagnostics, and hospital equipment—basically a “picks-and-shovels” provider for modern healthcare, with solid profits but not a classic hyper-growth story. > **📍 Basic Profile** > > Market Cap **$28.0 billion** · Health Care / Medical Technology · NASDAQ · Price **$61.51** > **⚡ 3 Things You Should Know** > > 1. 💰 Solid business, not flashy: GEHC is profitable, throws off cash, and earns a respectable **18.75% ROE**—so this looks more like a durable healthcare infrastructure name than a speculative med-tech bet. > > 2. 📈 Growth is okay, but the market wants more: long-term revenue growth has only been around **4%**, and the latest quarter had **sales growth but an EPS miss**, which helps explain why the stock has been weak recently. > > 3. 🏷️ Valuation has cooled off: after falling close to its **52-week low**, the stock now trades at about **14.6x earnings**, which is much less demanding than many healthcare tech names—basically, expectations have already come down. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Medium✋ | Net margin 9.1%, decent but not elite for med-tech | > | Growth Rate | Steady📈 | Revenue growth roughly 4% over 3–5 years | > | Financial Health | Moderate💛 | Debt-to-equity 96.8%, but interest coverage 10.3x helps | > | Valuation | Fair | PE 14.65x, with shares near the low end of 52-week range | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** GE HealthCare sells medical imaging equipment, diagnostics products, and patient-care technologies to hospitals, clinics, and healthcare systems, making money from both equipment sales and recurring service/consumables demand. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Imaging / diagnostic equipment | [Data unavailable] | ↑ | Recent Q1 growth was supported by Imaging and Pharmaceutical Diagnostics | | Patient care / healthcare solutions / services | [Data unavailable] | → | Likely steadier and less cyclical, but segment split not provided in the dataset | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 39.14% | Average | Good enough to show product value, but not software-like economics | | Net Margin | 9.1% | Average | Profitable, though not a super-high-margin med-tech business | | ROE | 18.75% | Good 15% | Shows the company generates solid returns on shareholder capital | --- #### 📈 How's the Growth? **Growth Assessment:** Steady Growth | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | 7.4% (Q1 2026) | 3.99% (3Y avg) | Slightly improving near term | | Profit Growth | [Data unavailable] | EPS growth 2.53% (3Y) | Slowing / uneven | **Growth Quality:** > What's interesting is that recent growth seems real on the revenue side, with Q1 sales up **7.4%**, but organic growth was only **2.9%** based on the news summary. In other words, the business is growing, but not all of that growth looks like pure underlying acceleration, and the EPS miss suggests margins or operating leverage still need work. --- #### 💰 Financial Health Check **One Sentence:** Think of it like a household with a stable salary and manageable debt—not in trouble, but not ultra-conservative either. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 96.78% debt-to-equity | <60% safe | ⚠️High | | Current Ratio | 1.22 | >1.5 healthy | ⚠️Tight | | Cash Flow | $4.85/share | >0 | ✅Positive | **Extra context:** Worth noting, the balance sheet is not weak, but it isn't pristine either. The good news is **interest coverage of 10.26x** suggests debt is serviceable, so this is more of a “watch leverage” situation than a red alert. --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $58.75 - 52-Week High: $89.77 - Current: $61.51, **near the low** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(8.9% position) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE 14.65x | [Data unavailable] | [Data unavailable] | | vs Peers | PE 14.65x | Industry avg [Data unavailable] | [Data unavailable] | **What the Current Valuation is Betting On:** > Basically, the current multiple says the market sees GEHC as a dependable but not fast-growing healthcare equipment company. At this price, investors are not paying for perfection—they're likely betting that stable execution, AI-enabled product upgrades, and modest growth recovery can support a rerating from depressed sentiment. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-04-29 | Q1 2026 results: revenue up 7.4% to about $5.13B, but EPS missed expectations | Neutral to Negative — sales were good, but the EPS miss likely hurt confidence | | 2026-04-29 | Multiple brokers cut price targets after earnings while keeping positive ratings | Neutral — sentiment softened, but analysts did not broadly abandon the name | | 2026-05-12 | Management presented at Bank of America Global Healthcare Conference | Neutral — usually matters more for tone and guidance than for immediate fundamentals | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 39.14% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | 9.1% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | 18.75% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | 3.99% (3Y avg) | [Data unavailable] | [Data unavailable] | → | | Profit Growth | 2.53% (EPS 3Y avg) | [Data unavailable] | [Data unavailable] | → | | EPS Growth | 2.53% (3Y avg) | [Data unavailable] | [Data unavailable] | → | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2026-03-31 | $1.07 | $0.99 | -7.55% Miss 😟 | | 2025-12-31 | $1.43 | $1.44 | +0.96% Beat 😀 | | 2025-09-30 | $1.07 | $1.07 | -0.16% Miss 😐 | | 2025-06-30 | $0.94 | $1.06 | +13.25% Beat 😀 | **Earnings Trend Interpretation:** GEHC's earnings delivery has been mixed rather than consistently strong. What you might care about is that the latest quarter broke the rhythm in the wrong direction: revenue beat a bit, but earnings missed, which usually tells the market that costs, mix, or execution are not landing as cleanly as hoped. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 18 firms | 64.3% | | Hold | 9 firms | 32.1% | | Sell | 1 firm | 3.6% | **Target Price:** [Data unavailable] ~ [Data unavailable] (Median [Data unavailable]) **vs Current Price:** [Data unavailable] **Insider Activity:** Net **buying** in recent filings, with open-market purchases from insiders in May 2026 > Insider buying usually isn't a guarantee, but it's generally a better signal than insider selling. Here, the recent purchases suggest management may view the post-earnings weakness as overdone. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Growth Quality Risk:** Revenue is growing, but long-term growth is still modest and recent organic growth appears lower than reported growth → If this continues, the stock may stay stuck in a “cheap for a reason” range. 2. **Margin / Execution Risk:** The latest quarter saw an EPS miss despite decent revenue growth → If costs keep rising or product mix worsens, earnings leverage may disappoint. 3. **Balance Sheet Flexibility Risk:** Debt-to-equity is on the high side and liquidity ratios are only fair → If the company faces a downturn or integration hiccups, financial flexibility could become more of a concern. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** GE HealthCare is a large, established medical technology company with a stable role in hospital imaging, diagnostics, and care infrastructure. > > **Key strength:** Its biggest advantage is that it combines solid profitability, positive cash generation, and a valuation that already looks much less demanding after the stock pullback. > > **Key risk:** The main concern is that growth and margin expansion may not be strong enough to quickly change market sentiment, especially after the recent earnings miss. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis